Metrics as of 10/16/2026, 08:50 AM (Berlin time), refresh in progress.
Precigen Stock
Precigen, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Helen Sabzevari
- Employees
- 160
- Market cap
- $2.6 B
- IPO
- 08/08/2013
Precigen, Inc. is an American company in the healthcare sector dedicated to the discovery and development of cutting-edge gene and cellular therapies. Headquartered in Germantown, the company was established in 1998 and previously operated under the name Intrexon Corporation until January 2020. Operating within the…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Precigen stock: price history
1D
-2.2%
1W
-5.3%
1M
+2.9%
6M
+82.3%
YTD
+72.2%
1Y
+104.0%
2Y
+728.3%
5Y
+54.8%
10Y
-72.7%
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~44% stronger price swings than usual
Precigen stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
1 more assignment (Enabler/Second row) Pro-only.
Precigen Inc. is a U.S.-based biotechnology company specializing in the discovery and development of gene and cell therapies. The company leverages proprietary platforms such as UltraVector for DNA construction and the Sleeping Beauty Transposon system for genetic modifications. Additionally, Precigen offers tools for precise DNA recombination, inducible gene systems such as RheoSwitch, and cancer therapy platforms including UltraCAR-T. With a focus on regenerative medicine and immunotherapies, the company addresses complex medical needs through innovative technological approaches in genetics.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Precigen
Analyst assessment of Precigen
PRICE TARGET LOW
US$18.00
CONSENSUS
US$18.00
MEDIAN
US$18.00
PRICE TARGET HIGH
US$18.00
0
STRONG BUY
11
BUY
4
HOLD
1
SELL
0
STRONG SELL
16
TOTAL · Buy
As of: 05/08/2026
Precigen stock metrics
P/E
-6.36
P/B
58.93
EV/EBITDA
-18.48
RETURN ON EQUITY
46.1%
NET MARGIN
36.5%
DEBT/EQUITY
2.26
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
45.9%
FLOAT SHARES
164,238,173
AVG. DAILY VOLUME (30D)
4,768,256
Insider transactions (SEC)
Thomasian Harry Jr.
Thomasian Harry Jr.
Thomasian Harry Jr.
Thomasian Harry Jr.
KINDLER JEFFREY B
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.2%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Precigen stock
What does Precigen do?
Precigen, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Helen Sabzevari, the company employs around 160 people.
The IPO was on 08/08/2013; the stock trades on NASDAQ under the ticker PGEN.
What do analysts say about Precigen stock?
16 analysts rate the stock, the consensus is Buy (as of 05/08/2026).
The average price target is US$18.00, ranging from US$18.00 to US$18.00, with a median of US$18.00.
This is an external assessment, not a statement by Market Jury.
When does Precigen report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 44% stronger than usual.
Does Precigen pay a dividend?
No, Precigen currently does not pay a dividend.
Which stocks are comparable to Precigen?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Precigen stock analyzed?
Clicking "Analyze stock" lets five strategies assess Precigen against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.